CCSVI is big money making business, MS is a big money making business especially to drug producing companies, CCSVI in MS patients has been known for years they have been having stents fitted at their own expense for years. But the cause of this has been ignored even by the MS Society. I know CCSVI is caused by a misaligned Atlas and MS does NOT even exist. How many millions and for how many years are they going to waste and how many lives will they ruin until they admit how valuable a trained Chiropractor's opinion is
///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
***********************************************************************************

CCSVI - research so far and next steps

So far, many studies have been published looking at how prevalent CCSVI is in people with MS, and also looking at the effects of treatment for CCSVI. Although none of the studies have been conclusive to date, more research is constantly being published that will shine a light on the potential relationship between CCSVI and MS.misaligned Atlas

Studies on prevalence

Many studies looking at the link between CCSVI and MS have been published. Some of these studies show a strong link between CCSVI and MS, and others show no link. This is likely to be caused by:

the differences in techniques used to detect CCSVI
different study sizes
the way the study was conducted.

Some of these studies have highlighted the need for standardised techniques when it comes to diagnosing and measuring CCSVI, as well as robust study design, in order to measure the true prevalence of CCSVI in people with MS. Research is underway to address these issues for future studies.

Buffalo study

One of the largest studies to date on the prevalence of CCSVI was carried out in Buffalo NY.
500 people were scanned by doppler scanning methods to detect signs of CCSVI:

56.1 per cent of 289 people with MS showed signs of CCSVI
22.7 per cent of 163 people without MS (healthy participants) also showed signs of CCSVI
38.1 per cent of 21 people with clinically isolated syndrome showed signs of CCSVI
42.3 per cent of 26 people who had other neurological conditions showed signs of CCSVI

Looking at this initial data, the study organisers have said these results suggest that CCSVI does not have a primary role in causing MS, but may be a result of MS.
1000 additional participants will now be examined for signs of CCSVI by more advanced screening methods in the second stage of the study, to get a more accurate picture of the prevalence of CCSVI in people with and without MS.

Based on these results, a small clinical trial involving 30 people with CCSVI is underway.

Italian study

Another large study looking at 1165 people with MS, 376 healthy volunteers and 226 people with other neurological conditions reported back in October 2012.
CCSVI was found in:

3.26% of people with MS
2.13% of healthy volunteers
3.1% of people with other neurological conditions

The researchers conducting the study, which is yet to be published in a peer-reviewed journal, said there were no statistically significant differences in the three groups.

Seven key NMSS funded CCSVI studies

In June 2010, the National MS Society and the MS Society of Canada announced $2.4 million of support for seven new research projects focusing on the role of CCSVI in MS.

Results from these seven key studies have started to be published.

Texas study

Researchers from the University of Texas Health Science Centre at Houston used various neurosonography techniques to measure blood outflow from the brain to establish whether any of the participants in the study fulfilled the criteria for CCSVI. As part of their study they replicated the ultrasound methods used in the original studies which identified CCSVI in people with MS.
Researchers assessed CCSVI in:

206 people with MS
70 people without MS

The researchers found that CCSVI was present in 3.88% of people with MS and 7.14% of people without, and that there were no significant differences in blood flow rates between people with MS and people without.

Canadian study

Researchers from the University of British Columbia and the University of Saskatchewan in Canada used ultrasound techniques and catheter venography - as used in the original CCSVI studies - to ascertain whether the study participants had CCSVI.
177 people took part in the study (79 with MS, 55 of their siblings and 43 unrelated people who didn’t have MS) across three different centres in Canada.
Using catheter venography the researchers found that the following fulfilled criteria for CCSVI:

2% of people with MS
2% of their siblings
3% of unrelated people without MS

Researchers also used ultrasound to look for evidence of CCSVI and found the following had signs of CCSVI:

44% of people with MS
31% of their siblings
45% of unrelated people without MS

Both sets of results showed no significant increase in prevalence of CCSVI in people with MS compared to people without MS.

Interventional studies

In addition to studies on prevalence, there have also been a few small scale clinical trials looking at the safety and effectiveness of treatment of CCSVI on people with MS.

These studies focused mainly on safety of the treatment. They also looked at things like relapse rate, disability status and also measured lesions in the brain on an MRI machine, but these studies were open labeled, meaning that placebo effects were not accounted for. It remains difficult to draw firm conclusions on the potential risks and benefits of CCSVI treatment in people with MS without doing larger, more controlled studies.

There are a number of studies that have looked at the risk of treatment for CCSVI. Some complications that have been described are:

developing clots in the vein
arrhythmias (disruptions to the heart beat and rhythm)
vein dissection (separation of the vein)
in-stent thrombosis (bleeding at the site of stent placement)
vein rupture
groin hematoma (collection of blood outside the blood vessel).

In May 2012 the US Food and Drug Administration (FDA) issued a safety communication on CCSVI which mentions reports of adverse events associated with treatment for CCSVI.

Larger randomised controlled trials looking at the safety and effectiveness of treatments for CCSVI in people with MS will hopefully give us a more accurate picture of the potential risks and benefits of treatment for CCSVI.

Until then, we do not recommend that people seek treatment for CCSVI outside of a properly regulated clinical trial.

Page tagged with:

CCSVI

my mess/ms

Tuesday, 22 July 2014

CCSVI-MS- too much money making - when will they wake up!!!!!!!!!!!!!!!!!and the MS Society justs sits by